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Heparin cofactor II (HCII) is a serpin whose thrombin
inhibition activity is accelerated by glycosaminogly-
cans. We describe the novel properties of a carboxyl-
terminal histidine-tagged recombinant HCII (rHCII-
CHis6). Thrombin inhibition by rHCII-CHis6 was
increased >2-fold at ;5 mg/ml heparin compared with
wild-type recombinant HCII (wt-rHCII) at 50–100 mg/ml
heparin. Enhanced activity of rHCII-CHis6 was reversed
by treatment with carboxypeptidase A. We assessed the
role of the HCII acidic domain by constructing amino-
terminal deletion mutants (D1–52, D1–68, and D1–75) in
wt-rHCII and rHCII-CHis6. Without glycosaminoglycan,
unlike wt-rHCII deletion mutants, the rHCII-CHis6 dele-
tion mutants were less active compared with full-length
rHCII-CHis6. With glycosaminoglycans, D1–68 and D1–75
rHCIIs were all less active. We assessed the character of
the tag by comparing rHCII-CHis6, rHCII-CAla6, and rH-
CII-CLys6 to wt-rHCII. Only rHCII-CHis6 had increased
activity with heparin, whereas all three mutants have
increased heparin binding. We generated a carboxyl-
terminal histidine-tagged recombinant antithrombin III
to study the tag on another serpin. Interestingly, this
mutant antithrombin III had reduced heparin cofactor
activity compared with wild-type protein. In a plasma-
based assay, the glycosaminoglycan-dependent inhibi-
tion of thrombin by rHCII-CHis6 was significantly
greater compared with wt-rHCII. Thus, HCII variants
with increased function, such as rHCII-CHis6, may offer
novel reagents for clinical application.
Serine protease inhibitors (serpins)1 are a class of highly
conserved proteins whose prototypical member is a1-proteinase
inhibitor (1, 2). Serpins function primarily to inhibit serine
proteases that are involved in many normal biological pro-
cesses including coagulation, fibrinolysis, inflammation,
wound healing, and tissue repair as well as some pathological
processes such as atherosclerosis and cancer metastasis (2).
Within the serpin superfamily is a subclass of glycosaminogly-
can-binding serpins (1–3). This group includes antithrombin III
(ATIII), heparin cofactor II (HCII), protein C inhibitor, prote-
ase nexin-1, and plasminogen activator inhibitor-1 (2). Glyco-
saminoglycans bound by these serpins include heparin, chon-
droitin sulfates, dermatan sulfate, and proteoglycans with
these molecules as side chains.
Serpins inhibit their target proteases by acting as suicide
substrates (1, 2). Serpins contain an exposed reactive site loop.
Within the reactive site loop of the serpin is the P1–P19 bond
(4). The target protease will recognize this reactive site bond
and attack it as a substrate. Once attacked, the serpin and
protease are caught in a 1:1 covalent complex in which the
protease is rendered inactive (5). The complex is then cleared
via receptor-mediated endocytosis (6–8).
Heparin cofactor II is a 65.5-kDa glycoprotein whose inhib-
itory activity is directed toward thrombin and chymotrypsin (9,
10). Unlike the physiologic thrombin inhibitor ATIII (11, 12),
HCII inhibition of thrombin is accelerated by both heparin and
dermatan sulfate (13, 14). Maximal rates of thrombin inhibi-
tion by HCII are seen in the presence of dermatan sulfate. As
many dermatan sulfate-containing proteoglycans are located
extravascularly it has been speculated that HCII is an ex-
travascular thrombin inhibitor (15–17).
Heparin cofactor II is unusual in that its reactive site bond is
Leu-Ser (18, 19). In the presence of glycosaminoglycan, HCII
inhibits thrombin through an unusual mechanism (2, 14, 20–
25). Heparin cofactor II contains a unique amino-terminal re-
gion that is highly acidic and thus referred to as the “acidic
domain.” In the absence of glycosaminoglycan, the acidic do-
main is believed to interact with the D-helix region, which is
highly basic. The D-helix region is involved in glycosaminogly-
can binding. When glycosaminoglycan is present, it has been
suggested that the acidic domain is displaced. The displaced
acidic domain is then able to interact with the anion-binding
exosite-1 of thrombin.
Standard procedures to purify HCII involve binding protein
to heparin-Sepharose (26, 27). However, a further investigation
of the HCII mechanism of action by mutagenesis of its glyco-
saminoglycan-binding region would disrupt purification of pro-
tein by heparin affinity. Therefore, we began to derive alterna-
tive purification protocols to avert this problem. Many
researchers have used a sequence consisting of six histidine
residues as an affinity ligand (28–30). By attaching this se-
quence to a protein, either the amino or carboxyl terminus,
protein can be purified with a specialized Ni21 matrix (31).
This method had been used successfully as an affinity purifi-
cation ligand (28–30). These data suggest that the histidine tag
is a benign addition to proteins to which it was attached
(28–30).
In this report we show the following: (a) carboxyl-terminal
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hexahistidine-tagged recombinant HCII (rHCII-CHis6) has en-
hanced progressive antithrombin and heparin cofactor activi-
ties and increased heparin-Sepharose binding compared with
wild-type recombinant HCII (wt-rHCII); (b) a region within the
amino terminus of HCII may interact with the carboxyl-termi-
nal hexahistidine of rHCII-CHis6; (c) carboxyl-terminal hexa-
histidine-tagged recombinant antithrombin III (rATIII-CHis6)
does not have these enhanced activities compared with wild-
type recombinant ATIII (wt-rATIII); and (d) the enhanced hep-
arin effect of rHCII-CHis6 is maintained in a plasma-based
thrombin inhibition assay. Collectively, these data suggest that
rHCII-CHis6 could be a novel anticoagulant therapy.
EXPERIMENTAL PROCEDURES
Mutagenesis and Expression of Recombinant Proteins—To facilitate
our studies of HCII, site-directed mutagenesis (35) was performed on
full-length HCII cDNA subcloned into the pBlueScript SK1 mutagenesis
and cloning vector (Stratagene, La Jolla, CA) (36) at two sites to encode
the identical amino acid sequence but with two nucleotide changes (at
base pairs 595 and 1255) that create unique restriction sites (NheI and
AflII) in the cDNA. DNA sequencing using a Sequenase version 2.0 kit
(Amersham Pharmacia Biotech) identified positive clones. Full-length
HCII cDNA containing these unique restriction sites was then subcloned
into the baculoviral transfer vector pVL1392 (PharMingen, La Jolla, CA)
via flanking EcoRI sites as described previously (36).
Using this new HCII cDNA, a cassette of the cDNA was then sub-
cloned into pBlueScript SK1 with XhoI and EcoRI. This cassette was
then used to prepare rHCII-CHis6, rHCII-CAla6, and rHCII-CLys6 by




respectively. We also used this construct to create the truncation mut-
ants D1–52-rHCII, D1–68-rHCII, and D1–75-rHCII, using the primers
59-ACATCTGCGTGGGGTGAGGGGGAGGAGGAC-39, 59ACATCTGC-
GTGGGGTGAAGACG-ACGACTAC-39, and 59-ACATCTGCGTGGGGT-
ATCGTCGACAGTCTG-39, respectively. By using the rHCII-CHis6 con-
struct, we created the truncation mutants D1–52-rHCII-CHis6, D1–68-
rHCII-CHis6, and D1–75-rHCII-CHis6 using the primers mentioned
above, respectively. DNA sequencing identified positive clones. A cas-
sette containing the carboxyl-terminal additions was then excised with
AflII and XbaI and subcloned into pVL1392 containing the full-length
HCII cDNA cut with the same restriction enzymes. All truncation
mutants were subcloned into pVL1392 using the restriction enzyme
EcoRI and screened for proper orientation.
A full-length human ATIII cDNA was obtained from ATCC (catalog
number 57224) in the vector pKT218. The ATIII-containing vector was
digested with PstI, and this insert contained 1.6 kilobase pairs of open
reading frame, including the signal peptide sequence, and was sub-
cloned into the baculoviral transfer vector pVL1392 cut with the same
restriction enzyme.
Using this wt-ATIII cDNA, a cassette of the cDNA was subcloned
into pBlueScript SK1 with SacI and XbaI. This construct was then
mutated (35) to form rATIII-cassette-CHis6 with the primer 59-G-
GTGCAAAGAATAAGAACATTTTA(GTG)6CTTAACACAAGGGTTGG-
C-39. DNA sequencing using Sequenase identified positive clones. The
mutated cassette was excised from pBlueScript with the restriction
enzymes NcoI and XbaI and subcloned into pVL1392 containing the
full-length ATIII gene cut using the same restriction enzymes.
HCII- and ATIII-containing pVL1392 constructs were co-transfected
with linearized Autographica californica nuclear polyhedrosis virus
into Spodoptera frugiperda (Sf 9) insect cells (Invitrogen, Carlsbad, CA)
in T25 flasks using BaculoGold Baculovirus Transfection Kits (PharM-
ingen, La Jolla, CA) as detailed previously (34, 36). Media were col-
lected from these cells 5 days post-transfection as recombinant viral
stock. Production of rHCII or rATIII mutants and wild-type protein was
verified by immunoblot analysis of whole cell lysates. Recombinant
viral stocks were amplified and stored at 280 °C. Sf9 cells were main-
tained in Grace’s medium supplemented with 10% fetal bovine serum,
0.3 g/liter L-glutamine, and 50 mg/ml gentamicin.
Protein Expression and Purification—Expression of both rHCII and
rATIII was performed using HighFivey insect cells (Invitrogen, Carls-
bad, CA) maintained at 27 °C in Excel 405 medium (JRH Biosciences,
Lenexa, KS). Most of the rHCII proteins were purified by sequential
heparin-Sepharose and Q-Sepharose chromatography steps as de-
scribed previously (34, 36). However, the cleared media of D1–68-
rHCII, D1–75-rHCII, D1–68-rHCII-CHis6, and D1–75-rHCII-CHis6
were loaded on a 5-ml Hi-Trap heparin-Sepharose column using an
FPLC System (Amersham Pharmacia Biotech) equilibrated with HNPN
buffer (20 mM Hepes, pH 7.4, 150 mM NaCl, 0.1% PEG, 0.05% NaN3 ) at
pH 7.4, washed with 25 ml of HNPN, and then eluted with a linear
gradient from 50 mM to 2 M NaCl, 20 mM Hepes, pH 7.4, 0.1% PEG, and
0.02% NaN3.
The preparation and purification of the rATIII proteins began by
infecting four T150 flasks of sub-confluent HighFiveTM cells on day 1
with specific recombinant viral stocks. Two to three days post-infection,
media were decanted from cells, and cell debris was spun out by cen-
trifugation at 350 3 g for 10 min in a Centra-8 centrifuge (International
Equipment Co., Needham Heights, MA). The cleared medium (;100
ml) was diluted with an equal volume of a buffer made up of 20 mM
Hepes, pH 6.5, 0.2% PEG, and 0.02% NaN3. One ml of a 1:1 slurry of
heparin-Sepharose in HNPN buffer was added to the diluted media and
tumbled at 4 °C for 1 h. Heparin-Sepharose beads were then pelleted at
50 3 g for 5 min and washed two times with 20 mM Hepes, pH 7.4, 750
mM NaCl, 0.1% PEG, and 0.02% NaN3. The protein was eluted off of
heparin-Sepharose with 20 mM Hepes, pH 7.4, 2.0 M NaCl, 0.1% PEG,
and 0.02% NaN3.
Recombinant Protein Immunodetection—Concentrations of rHCII
and rATIII were determined by enzyme-linked immunosorbent assay
using purified plasma proteins as the standard, and rabbit antihuman
antithrombin III antibody was from Dako Corp. (Carpinteria, CA);
monoclonal antibody 2-4-34 to human HCII was prepared in our labo-
ratory, and a goat anti-human HCII IgG (catalog number GAHC2-IG)
was from Enzyme Research Laboratories (South Bend, IN). Immuno-
blot analysis was carried out using a Phast System (Amersham Phar-
macia Biotech) (34, 36).
Protease Inhibition—Protease inhibition rates were determined as de-
scribed previously (14, 17, 34, 36). All assays were performed at room
temperature in 96-well microtiter plates previously coated with 2 mg/ml
BSA.
In the absence of glycosaminoglycan, 5–150 nM rHCII (wt, CHis6,
CHis5Pro, CAla6, CLys6, D1–52, D1–68, D1–75, D1–52-CHis6, D1–68-
CHis6, and D1–75-CHis6) or rATIII (wt or CHis6) was incubated with
0.5–1 nM a-thrombin, 1 nM gT-thrombin, 0.5 nM Factor Xa, 2 nM chy-
motrypsin, or 5 nM trypsin, in the presence of 1 mg/ml Polybrene (pB)
(for thrombin and Factor Xa) and 2 mg/ml BSA in HNPN, pH 7.4.
In the absence of glycosaminoglycan either hirugen or a control
peptide corresponding to the reverse sequence of the HCII acidic do-
main (residues 47–61) at 20 mM and rHCII (wt at 200 nM and CHis6 at
100 nM) were incubated with 1 nM thrombin in the presence of 1 mg/ml
pB and 2 mg/ml BSA in HNPN, pH 7.4 (37).
In the presence of either heparin (10 or 100 mg/ml) or dermatan
sulfate (100 mg/ml), 0.5 nM thrombin was incubated with 20 mM hirugen
peptide or control peptide and 10 nM wt-rHCII or rHCII-CHis6 in the
presence of 2 mg/ml BSA in HNPN, pH 7.4.
In the presence of glycosaminoglycans or sulfated polyanions, 5–10
nM rHCII (wt, CHis6, CHis5Pro, CAla6, CLys6, D1–52, D1–68, D1–75,
D1–52-CHis6, D1–68-CHis6, and D1–75-CHis6) was incubated with 0.5
nM thrombin, and 0–1 mg/ml heparin, 0–4 mg/ml dermatan sulfate,
0–6 mg/ml desmin (a gift from Dr. Egidio Marchi of Alfa Wassermann,
S.p.A.), or 0–100 mg/ml fucoidan, or 10 nM rATIII (wt or CHis6) was
incubated with 1 nM thrombin or factor Xa and 0–1 mg/ml heparin in
the presence of 2 mg/ml BSA in HNPN, pH 7.4.
Residual thrombin activity was measured with 150 mM Gly-Pro-
Arg-NA and 1 mg/ml pB in the absence of glycosaminoglycan, 2 mg/ml
pB in the presence of heparin or fucoidan, 4 mg/ml pB in the presence
of dermatan sulfate, and 6 mg/ml pB in the presence of desmin. Resid-
ual factor Xa activity was measured with 500 mM Spectrozyme FXa and
2 mg/ml pB in the presence or absence of glycosaminoglycan. Residual
chymotrypsin activity was measured with 150 mM Ala-Ala-Pro-Phe-NA,
and residual trypsin activity was measured with 150 mM Gly-Pro-Arg-
NA. Substrate cleavage was measured by color development at 405 nM
on a Vmax Kinetic Microplate Reader (Molecular Devices).
Assays were performed at least in triplicate on two or more recom-
binant protein preparations. All inhibition studies were measured un-
der pseudo-first order conditions where inhibitor [I] is at least 10-fold
higher than enzyme (protease) [E], and second-order rate constants
were calculated as described previously (34, 36).
Heparin-Sepharose Affinity Chromatography—To determine relative
heparin affinities, 3–6 mg of rHCII protein was diluted in 20 mM Hepes,
pH 7.4, and was run either on a 1-ml heparin-Sepharose or a 2-ml
Hi-Trap heparin-Sepharose column (equilibrated in 20 mM Hepes, pH
7.4, and 50 mM NaCl) using an FPLC® System (Amersham Pharmacia
Biotech). After the samples were loaded on the column, the proteins
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were eluted with a 40-ml gradient of 20 mM Hepes, pH 7.4, from 50 to
800 mM NaCl for heparin-Sepharose, and from 150 mM to 2 M NaCl for
Hi-Trap heparin-Sepharose, and 1-ml fractions were collected. 100 ml of
each fraction was aliquoted onto a 96-well microtiter plate, and enzyme-
linked immunosorbent assay (protocol shown above) was performed.
The peak elution ionic strength was determined by plotting 405 nm
color development and NaCl concentration against the fraction number.
All samples were run at least in triplicate using two or more protein
preparations. Recombinant ATIII samples were run similarly to the
HCII samples using heparin-Sepharose, except the elution gradient
was run from 50 mM to 2 M NaCl.
Carboxypeptidase A Treatment—CPA stored in toluene was washed
with distilled H2O and then dialyzed into HNPN buffer at pH 7.4. 40 ng
of CPA was combined with approximately 1 mg of recombinant protein
and incubated at room temperature. Following a 2-h incubation at room
temperature, 2 mM EDTA was added to quench CPA activity. Controls
were run in which EDTA was added to the reaction prior to the addition
of CPA. CPA-digested proteins were then assayed according to previ-
ously mentioned procedures.
Plasma Assays—Human antithrombin III-deficient plasma (catalog
number 203) and normal hemostasis reference plasma (catalog number
258N) were purchased from American Diagnostica (Greenwich, CT).
The assay to evaluate rHCII (wt and rHCII-CHis6) in plasma was
designed based on previously published methods (38, 39). All assays
were performed at room temperature in 96-well microtiter plates pre-
viously coated with 2 mg/ml BSA. This assay was performed using
normal hemostasis reference plasma (REF), human antithrombin III-
deficient plasma (DEF), or a 50:50 mixture of these plasmas (REF/
DEF). Within the assay, 10 nM rHCII or rHCII-CHis6 was incubated for
15 s with 1 nM thrombin and 1 mg/ml heparin or 50 mg/ml dermatan
sulfate, in the presence of a 1:100 dilution of plasma. Residual thrombin
activity was measured with 300 mM GPA and 2 mg/ml pB. Substrate
cleavage was measured by color development at 405 nM on a Vmax
Kinetic Microplate Reader. Second order rate constants were measured
at least in triplicate on two recombinant protein preparations as de-
scribed above.
Statistical Analysis—The statistical significance of the data in Ta-




HCII proteins were generated using Kunkel’s method of oligo-
nucleotide-directed mutagenesis. More specifically, rHCII-
CHis6 was made by inserting six histidine codons directly be-
fore the TAG stop codon. By using a baculoviral expression
system, we typically obtained ;60 mg of protein from four T150
flasks of HighFiveTM cells infected with recombinant viral
stock. After purification, immunoblot analysis showed that rH-
CII-CHis6 was a single band that co-migrated with wt-rHCII.
We have compared the rates of inhibition of thrombin and
chymotrypsin by rHCII-CHis6 and wt-rHCII (Table I). In the
absence of glycosaminoglycan, the rate of thrombin inhibition
by rHCII-CHis6 is significantly faster (1.5-fold) than that of
wt-rHCII. However, when comparing the same proteins in
their ability to inhibit chymotrypsin, we see that wt-rHCII and
rHCII-CHis6 are essentially the same.
The antithrombin properties of wt-HCII can be enhanced
more than 10,000-fold by the addition of glycosaminoglycans
such as heparin or dermatan sulfate. The carboxyl-terminal
histidine-tagged HCII influences the heparin-accelerated anti-
thrombin activity. As shown in the top panel of Fig. 1, the
maximal rate of wt-rHCII inhibition of thrombin is 9.29 6
2.8 3 108 M21 min21 at 50–100 mg/ml heparin. However, we see
over a 2-fold increase in the rate of thrombin inhibition by
rHCII-CHis6 at 2.23 6 .43 3 10
9 M21 min21 at only 5 mg/ml
heparin. Therefore, in addition to the increase in rate, we also
see an approximate 20-fold decrease in the amount of heparin
required for maximal activity. These results are summarized in
Table II and indicate that the histidine tag augmented the
ability of HCII to inhibit thrombin in the presence of heparin.
Addition of an Na-acetylated hexahistidine peptide at 1,000
molar excess to wt-rHCII had neither a positive nor a negative
effect on the heparin cofactor activity of HCII (data not includ-
ed). These data suggest that the rate of thrombin inhibition by
rHCII-CHis6 with heparin is increased over 100,000-fold and is
comparable to rates obtained with the physiologic thrombin
inhibitor ATIII with heparin.
We do not see any change in rates of thrombin inhibition in
the presence of the glycosaminoglycan, dermatan sulfate. As
shown in the bottom panel of Fig. 1, the maximal rate of
thrombin inhibition is 1.52 6 0.31 3 109 M21 min21 for wt-
rHCII, and 1.80 6 0.50 3 109 M21 min21 for rHCII-CHis6
maximal inhibition is seen at approximately 500 mg/ml derma-
tan sulfate for both proteins. These data, which are also sum-
marized in Table II, indicate that the addition of the carboxyl-
terminal histidine tag does not affect the rate at which
thrombin inhibition by HCII is accelerated by dermatan
sulfate.2
2 We determined the ability of two other sulfated polysaccharides to
accelerate thrombin inhibition by HCII. In the presence of fucoidan, we
TABLE I
HCII Inhibition of thrombin and chymotrypsin in the absence of glycosaminoglycans
Inhibition of proteases by rHCII mutants was measured in the absence of glycosaminoglycans as described under “Experimental Procedures.”
Values are expressed as means 6 S.D.
Serpin Thrombin k2 3 10




wt-rHCII 1.3 6 0.19 71 6 12
rHCII-CHis6 1.9 6 0.10
b 1.5 61 6 16c 0.86
rHCII-CAla6 1.7 6 0.41
d 1.5 48 6 7.6e 0.77
rHCII-CLys6 1.5 6 0.38
e 1.4 56 6 5.7e 0.90
D1–52-rHCII 1.4 6 0.19d 1.3 61 6 17e 0.98
D1–68-rHCII 1.0 6 0.42e 0.90 102 6 31d 1.6
D1–75-rHCII 1.2 6 0.26e 1.1 86 6 27e 1.4
D1–52-rHCII-CHis6 0.95 6 0.15
g 0.53f 38 6 9.1g 0.66f
D1–68-rHCII-CHis6 0.56 6 0.26
g 0.31f 30 6 2.3g 0.52f
D1–75-rHCII-CHis6 0.71 6 0.15
g 0.39f 12 6 7.0g 0.21f
a Rate constants are the mean values of 3–9 separate determinations with at least 3 different preparations of recombinant protein.
b p # 0.003 compared with wt-rHCII.
c Not statistically different from wt-rHCII.
d p # 0.05 compared with wt-rHCII (using the values 1.1 6 .05 3 104 and 62 6 14 3 104 M21min21 for thrombin and chymotrypsin, respectively).
e Not significantly different from wt-rHCII (using the values 1.1 6 .05 3 104 and 62 6 14 3 104 M21min21 for thrombin and chymotrypsin,
respectively).
f Ratio calculated as mutant/rHCII-CHis6
g p # 0.05 compared with rHCII-CHis6 (using the values 1.8 6 .05 3 10
4 and 58 6 18 3 104 M21 min21 for thrombin and chymotrypsin,
respectively).
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We further assessed the ability of these proteins to bind
heparin-Sepharose. As shown in Table II, rHCII-CHis6 eluted
at almost two times the NaCl concentration as wt-rHCII, 575
mM versus 350 mM, respectively. Taken together with the en-
hanced heparin cofactor activity of rHCII-CHis6, these data
imply that the hexahistidine tag endows HCII with increased
heparin binding.
To ensure that the enhanced activity of rHCII-CHis6 could be
attributed to the histidine tag, we attempted to remove the tag
using the exopeptidase CPA. CPA removes amino acids from
the carboxyl terminus of proteins; however, it is unable to
cleave arginine, lysine, or proline. There is an arginine at the
second to last position of the native HCII. Therefore, we as-
sumed a CPA digest would remove the hexahistidine tag and
the final serine residue of HCII stopping at the penultimate
arginine. In the top panel of Fig. 2, we see that a rHCII-CHis6
pre-CPA digest shows an increased rate of thrombin inhibition
and a shift to a lower heparin requirement. When digested with
CPA, the curve of thrombin inhibition shifts to lower rates of
inhibition and the required heparin concentration increases. In
contrast, the curves of thrombin inhibition by wt-rHCII do not
drastically change before or after the CPA digest (Fig. 2, middle
panel). Control experiments with EDTA added to rHCII-CHis6
prior to the exopeptidase verified that the loss of rHCII-CHis6
activity was due to the effect of active CPA.
To confirm that the function of CPA in reversing the en-
hanced activity was on the hexahistidine sequence, we ex-
pressed a mutant that had a His5Pro carboxyl-terminal tag.
rHCII-CHis5Pro inhibits thrombin in the absence of glycosami-
noglycans (3.2 3 104 M21 min21) at rates ;2-fold higher than
wt-rHCII and has increased heparin cofactor activity at a lower
maximal heparin concentration (1.87 6 0.37 3 109 M21 min21
at 10 mg/ml heparin; data not included). We hypothesized that
this mutant should be resistant to CPA digestion because of the
carboxyl-terminal proline residue. Pre-digested rHCII-
CHis5Pro has similar properties to that of rHCII-CHis6 with an
increased inhibition rate and a lower heparin requirement;
however, as expected, its activity does not change appreciably
after treatment with CPA (Fig. 2, bottom panel).
Thrombin inhibition in the presence of hirugen was per-
formed to examine the potential role of thrombin anion-binding
exosite-1 (ABE-1) in the enhanced activity of rHCII-CHis6.
Hirugen has a similar effect on antithrombin activity (without
glycosaminoglycan) of rHCII-CHis6 and wt-rHCII, with rates
reduced .50% (Fig. 3). The effect of hirugen is specific since a
control peptide did not significantly block the rHCII-thrombin
reactions (Fig. 3). In the presence of either 100 mg/ml heparin
(optimal for wt-rHCII) or dermatan sulfate (optimal for wt-
rHCII and rHCII-CHis6), both wt-rHCII and rHCII-CHis6 lose
.85% of their inhibitory activity in the presence of hirugen
(Fig. 3). In the presence of 10 mg/ml heparin (optimal for rHCII-
CHis6) and hirugen, we see that wt-rHCII loses 90% of its
inhibitory potential, whereas rHCII-CHis6 loses 70% of its in-
hibitory activity (Fig. 3). These data imply that the hexahisti-
dine tag does not alter the manner in which HCII interacts
with ABE-1 of thrombin.3
Amino-terminal Deletion Mutants of wt-rHCII and rHCII-
CHis6—To assess the role of the acidic domain on HCII activ-
ity, we prepared amino-terminal deletions of rHCII with and
without CHis6. By using either a wt-rHCII or rHCII-CHis6
single-stranded DNA template, we deleted amino acids 1–52,
1–68, or 1–75. From each 100-ml culture infected with recom-
binant baculoviral stock, we purified ;150 mg of protein. As
expected, immunoblot analysis showed that purified D1–52-
rHCII, D1–68-rHCII, and D1–75-rHCII (with and without
CHis6) were sequentially smaller than wt-rHCII.
In the absence of glycosaminoglycan, each of the six amino-
terminal deletion mutations was compared with either wt-
rHCII or rHCII-CHis6 for thrombin and chymotrypsin inhibi-
tion (Table I). Deletion of the first 52 amino acids, but not for
the 68 or 75 deletions, slightly but significantly increases the
rate of thrombin inhibition in the untagged rHCII compared
with wt-rHCII. Chymotrypsin inhibition by D1–68-rHCII is
significantly faster than wt-rHCII; however, D1–52- and D1–
75-rHCII show no significant differences in the rates of chymo-
trypsin inhibition (Table I). In contrast, the three deletions in
the hexahistidine-tagged rHCII resulted in significant de-
creases in both thrombin and chymotrypsin inhibition activity
compared with rHCII-CHis6 (Table I). Deletion of the amino
terminus, beginning with D1–52, drastically affects protease
inhibition by CHis6-tagged rHCII and may indicate that an
interaction between the amino- and carboxyl-terminal regions
of HCII is eliminated that leads to the loss of activity.
In the presence of heparin, D1–52-rHCII had similar activity
see no shift in the optimal concentration required to accelerate rHCII-
CHis6 compared with wt-rHCII (data not shown). The maximal rate of
thrombin inhibition by wt-rHCII (2.38 6 0.42 3 107 M21 min21) is
similar to that of rHCII-CHis6 (3.21 6 0.16 3 10
7 M21 min21). In the
presence of desmin, a low molecular weight dermatan sulfate, the
optimal desmin concentrations for maximal inhibition of thrombin by
either wt-rHCII (k2 of 5.37 6 0.29 3 10
8 M21 min21) or rHCII-CHis6 (k2
of 2.57 6 0.33 3 108 M21 min21) are similar.
3 Inhibition of gT-thrombin by wt-rHCII and rHCII-CHis6 was com-
pared with further study of the role of ABE-1 of thrombin. In the
absence of glycosaminoglycan, thrombin inhibition by rHCII-CHis6
(7.93 6 1.0 3 103 M21 min21) is significantly faster (2-fold) than wt-
rHCII (3.81 6 0.30 3 103 M21 min21). In the presence of heparin and
dermatan sulfate, the rates of gT-thrombin inhibition by either wt-
rHCII or rHCII-CHis6 are greatly reduced in comparison to inhibition
rates with a-thrombin (data not shown). These data agree with the
currently accepted mechanism of thrombin inhibition by HCII.
FIG. 1. Inhibition of thrombin by wt-rHCII and rHCII-CHis6 in
the presence of heparin and dermatan sulfate. Thrombin inhibi-
tion assays in the presence of glycosaminoglycan were performed as
detailed under “Experimental Procedures” with a-thrombin and in-
creasing amounts of heparin (top panel) and dermatan sulfate (bottom
panel) comparing wt-rHCII (M) and rHCII-CHis6 (E). The curves shown
are averages of two or three recombinant protein preparations assayed
two to three times each.
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to wt-rHCII to accelerate thrombin inhibition (Table III). How-
ever, the 68 and 75 deletions have substantially decreased
thrombin inhibition in the presence of heparin by almost 200–
250-fold in comparison to full-length wt-rHCII (Table III). The
deletions that contained the hexahistidine tag all showed dif-
ferences compared with rHCII-CHis6 (Table III). Unlike D1–
52-rHCII, D1–52-rHCII-CHis6 had a significantly decreased
thrombin inhibition with heparin (Table III). Likewise, the 68
and 75 hexahistidine-tagged deletions have even greater de-
creases in heparin-accelerated thrombin inhibition compared
with full-length rHCII-CHis6 (Table III). As noted previously
(22), deletion of the acidic domain of rHCII leads both to a
successive reduction in the peak heparin concentration at
which maximal thrombin inhibition occurs and to increased
NaCl elution from a Hi-Trap Heparin-Sepharose matrix,
whether containing wt-rHCII or rHCII-CHis6 (Table III). In the
presence of dermatan sulfate, a similar pattern was found for
both wt-rHCII and rHCII-CHis6 deletion constructs (Table III).
Overall, these data agree with previous work concerning the
masking of glycosaminoglycan binding properties of HCII by its
amino-terminal acid domain region (22). It is notable that the
results for D1–52-rHCII-CHis6 may suggest a potential inter-
action between this portion of the amino terminus of HCII with
its own carboxyl terminus.
Carboxyl-terminal Alanine- and Lysine-tagged rHCII—To
assess the character of the carboxyl-terminal tag on HCII ac-
tivity, we inserted six alanine or lysine codons directly before
the TAG stop codon and made rHCII-CAla6 and rHCII-CLys6.
We typically obtained ;125 mg of protein from a 100-ml culture
infected with recombinant baculoviral stock. Immunoblot anal-
ysis showed that purified rHCII-CAla6 and rHCII-CLys6 co-
migrated with wt-rHCII.
In the absence of glycosaminoglycan, the rate of thrombin
inhibition by rHCII-CHis6 and rHCII-CAla6, but not by rHCII-
CLys6, was significantly faster than wt-rHCII (Table I). In
contrast, the carboxyl-terminal hexapeptide-tagged rHCIIs
(His6, Ala6, or Lys6) did not have rates of chymotrypsin that
differed significantly from wt-rHCII (Table I). Thus, comparing
chymotrypsin to thrombin inhibition, the data imply that the
carboxyl-terminal tags do not drastically affect the conforma-
tion of the reactive site loop of full-length rHCII.
In the presence of heparin, we found the alanine and lysine
tags had different effects on the rate of thrombin inhibition
compared with rHCII-CHis6 (Fig. 4 and Table III). Although
rHCII-CLys6 has a similar inhibitory rate to wt-rHCII, it does
demonstrate the shift of the inhibition maximum to a lower
heparin concentration (20 mg/ml) similar to but not the same as
rHCII-CHis6 (10 mg/ml). Recombinant HCII-CAla6 was reduced
in activity but has the similar heparin maximum as wt-rHCII.
In the presence of dermatan sulfate, thrombin inhibition by
rHCII-CHis6 is similar to wt-rHCII, but the rates for both
rHCII-CAla6 and rHCII-CLys6 are significantly reduced with a
similar maximal dermatan sulfate concentration ranging from
100 to 200 mg/ml (Fig. 4 and Table III). Both rHCII-CHis6 and
rHCII-CLys6 eluted at a significantly higher ionic strength
than wt-rHCII by Hi-Trap Heparin-Sepharose chromatogra-
TABLE II
HCII and ATIII inhibition of serine proteases in the presence of glycosaminoglycans
Inhibition of serine proteases by rHCII and rATIII mutants was measured in the presence of increasing concentrations of either heparin or
dermatan sulfate (DSO4). The maximal inhibition of each curve was used in the calculation of the average inhibition rate. Values are expressed
as means 6 S.D. The number in parentheses that follows indicates the average glycosaminoglycan concentration at which the maximal rate was
measured. The final column indicates the peak NaCl concentration at which each variant eluted from heparin-Sepharose. All assays were
performed as described under “Experimental Procedures.”


















21min21 M21min21 M21min21 mM
wt-rHCII 9.29 6 2.8 (50)b 15.2 6 3.1 (500) 350
rHCII-CHis6 22.3 6 4.3
c (5) 2.4 18.0 6 5.0d (500) 1.2 575
wt-rATIII 5.26 6 .68 (1) 1.41 6 0.39 (10) 975
rATIII-CHis6 2.87 6 .54
e (2) .55 0.785 6 0.28e (10) 0.56 975
a Rate constants are the mean values of 3–6 separate determinations on at least 3 different protein preparations.
b Values in parentheses indicate optimal heparin concentration.
c p # 0.029 compared with wt-rHCII.
d Not statistically different from wt-rHCII.
e p # 0.020 compared with wt-rATIII.
FIG. 2. Carboxypeptidase A reversibility of rHCII mutants.
Thrombin inhibition assays in the presence of heparin were performed
as detailed under “Experimental Procedures” with a-thrombin and
increasing amounts of heparin. The top panel shows the curves for
rHCII-CHis6 pre- (E) and post-CPA (●) digest. The middle panel shows
the curves for wt-rHCII pre- (M) and post-CPA (f) digest. The bottom
panel shows the curves for rHCII-CHis5Pro pre- (‚) and post-CPA (Œ)
digest. The curves shown are representative data.
Increased Anticoagulant Activity of His6-tagged HCII34560
phy, whereas rHCII-CAla6 eluted at a slightly higher NaCl
concentration than wt-rHCII (Table III). These results suggest
that a unique interaction may occur between hexahistidine and
HCII, which is not manifest by either hexa-alanine or hexal-
ysine attached to the carboxyl terminus of rHCII.
Carboxyl-terminal Histidine-Tagged rATIII—To examine
whether augmentation of activity was a general phenomenon of
other glycosaminoglycan-binding serpins, we added a hexahis-
tidine carboxyl tag to recombinant wild-type ATIII. Again we
used Kunkel’s method to insert six histidine codons directly
before the TAA stop codon. We used a baculoviral expression
system, and 60–150 mg of protein was obtained from four T150
flasks of HighFiveTM cells infected with recombinant viral
stock. Immunoblot analysis showed that purified rATIII-CHis6
co-migrated with wt-rATIII as a single band.
As a control to evaluate recombinant ATIII proteins, we
obtained inhibition rates of 1.32 6 0.22 3 105 M21 min21 and
9.15 6 0.44 3 104 M21 min21 for thrombin and Factor Xa with
human plasma-derived ATIII in the absence of glycosaminogly-
can, respectively. The rates of thrombin (8.81 6 1.3 3 104 M21
min21) and trypsin (180 6 91 3 105 M21 min21) inhibition by
rATIII-CHis6 are essentially unchanged as compared with wt-
rATIII (10.4 6 2.3 3 104 M21 min21 and 184 6 57 3 104 M21
min21 for thrombin and trypsin, respectively). However, the
rate of Factor Xa inhibition by rATIII-CHis6 is 9.87 6 0.57 3
104 M21 min21, which is significantly lower than wt-rATIII
(16.4 6 1.2 3 104 M21 min21).
Fig. 5 shows the heparin-catalyzed ATIII inhibition of throm-
bin (top panel) and Factor Xa (bottom panel). We see that there
is an almost 2-fold slower rate of thrombin inhibition by rATIII-
FIG. 3. Effect of hirugen on the rate of thrombin inhibition by wt-rHCII and rHCII-CHis6. Wild-type-rHCII and rHCII-CHis6 were
incubated with a-thrombin in the absence and presence of glycosaminoglycan in the presence of hirugen (o), in the absence of hirugen (f), or in
the presence of control peptide (M). Residual thrombin activity was determined as described under “Experimental Procedures.” The data are
presented as normalized percent maximal rate of inhibition using the following rate constants of inhibition (k2) in the absence of peptide: with no
glycosaminoglycan, wt-rHCII is 1.52 3 104 M21 min21 and rHCII-CHis6 is 1.86 3 10
4 M21 min21; in the presence of 10 mg/ml heparin, wt-rHCII
is 1.90 3 108 M21 min21 and rHCII-CHis6 is 2.40 3 10
8 M21 min21; in the presence of 100 mg/ml heparin, wt-rHCII is 2.20 3 108 M21 min21 and
rHCII-CHis6 is 2.20 3 10
8 M21 min21; in the presence of 100 mg/ml dermatan sulfate, wt-rHCII is 2.50 3 108 M21 min21 and rHCII-CHis6 is 1.80 3
108 M21 min21. The above data represent the means of two determinations in triplicate.
TABLE III
HCII Inhibition of thrombin in the presence of glycosaminoglycans
Inhibition of thrombin by rHCII mutants was measured in the presence of increasing concentrations of either heparin or dermatan sulfate. The
maximal inhibition of each curve was used in the calculation of the average inhibition rate. Values are expressed as means 6 S.D. The number
in parentheses that follows indicates the average glycosaminoglycan concentration at which the maximal rate was measured. The final column
indicates the peak NaCl concentration at which each variant eluted from Hi-Trap heparin-Sepharose. All assays were performed as described
under “Experimental Procedures.”












wt-rHCII 63 6 10 (100) 87 6 9.1 (200) 540
rHCII-CHis6 149 6 46 (10)
b 2.4 69 6 16 (200)c 0.79 740
rHCII-CAla6 35 6 11 (100)
b 0.56 48 6 20 (200)b 0.55 610
rHCII-CLys6 51 6 11 (20)
c 0.81 32 6 5.6 (100)b 0.38 740
D1–52-rHCII 78 6 7.4 (20)b 1.2 69 6 7.7 (200)c 0.79 600
D1–68-rHCII 0.39 6 0.16 (2)b 0.0062 0.044 6 0.019 (20)b 0.00051 800
D1–75-rHCII 0.30 6 0.061 (2)b 0.0048 0.018 6 0.0008 (20)b 0.00021 1200
D1–52-rHCII-CHis6 51 6 4.5 (10)
d 0.34e 21 6 1.4 (100)d 0.30e 600
D1–68-rHCII-CHis6 0.64 6 0.093 (2)
d 0.0043e 0.030 6 0.0056 (20)d 0.00043e 1100
D1–75-rHCI-CHis6 0.29 6 0.13 (2)
d 0.0019e 0.010 6 0.0044 (20)d 0.00014e 1200
a Rate constants are mean values of 3–6 determinations with at least 3 preparations of recombinant protein preparations.
b p # 0.05 compared with wt-rHCII.
c Not significantly different from wt-rHCII.
d p # 0.05 compared with rHCII-CHis6.
e Ratio calculated as mutant/rHCII-CHis6
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CHis6 (2.87 6 0.54 3 10
8 M21 min21) as compared with wt-
rATIII (5.26 6 0.68 3 108 M21 min21). The rates of Factor Xa
inhibition in the presence of heparin show the same trend.
Proteolysis of rATIII-CHis6 with CPA should, theoretically,
remove the entire histidine tag leaving the intact native pro-
tein since the final amino acid of ATIII is lysine. Rates of
thrombin inhibition by rATIII-CHis6 with 10 mg/ml heparin
increased 40% after treatment with CPA, compared with wt-
rATIII (data not shown). To compare the recombinant ATIII
proteins to plasma-derived ATIII with heparin, we obtained
maximal rates of inhibition of 6.94 6 0.25 3 108 M21 min21 and
2.51 6 0.083 3 108 M21 min21, for thrombin and Factor Xa,
respectively (Fig. 5). The curves in Fig. 5 illustrate that the
amount of heparin required for maximal inhibition of either
thrombin or Factor Xa by these ATIII derivatives does not
change significantly when the histidine tag is added. The data
are summarized in Table II.
We then assessed the ability of the rATIII molecules to bind
heparin-Sepharose. As shown in Table II, rATIII-CHis6 eluted
at the same NaCl concentration as wt-rATIII (975 mM). These
data support the previous data showing no shift in the amount
of heparin required for antithrombin or anti-Factor Xa activity.
Histidine-tagged rHCII in Plasma-based Thrombin Inhibi-
tion Assays—The data that have been presented to this point
indicate that rHCII-CHis6 is an excellent thrombin inhibitor
and is now comparable to the physiologic inhibitor ATIII in its
rates and heparin requirements. The next set of experiments
was performed to assess the potential of rHCII-CHis6 as a
therapeutic agent in a more physiologic based setting (i.e.
plasma).
The results comparing rHCII-CHis6 to wt-rHCII are summa-
rized in Table IV. At each plasma condition the rates of throm-
bin inhibition were measured in the presence of 1 mg/ml hep-
arin. The thrombin inhibitory capabilities of rHCII-CHis6 with
each plasma condition are significantly greater than those of
wt-rHCII performed using the same conditions. Thrombin in-
hibition in REF plasma, which would contain both HCII and
ATIII, gave thrombin inhibition rates that are increased 1.5-
fold for rHCII-CHis6 compared with wt-rHCII. Using DEF
plasma, which is totally deficient in ATIII, the enhancement of
thrombin inhibition by rHCII-CHis6 over wt-rHCII was more
apparent with a 4.6-fold increased rate. In a 50:50 mixture of
REF/DEF, which mimics a heterozygous ATIII deficiency, rH-
CII-CHis6 inhibition of thrombin was increased 1.5-fold com-
pared with wt-rHCII. Furthermore, the rates of inhibition in
the presence of 50 mg/ml of dermatan sulfate are also signifi-
cantly greater with rHCII-CHis6 than with wt-rHCII for each
of the plasma conditions tested, with rates increased about
1.2–1.3-fold (Table IV). These data suggest that rHCII-CHis6 is
a significantly better thrombin inhibitor than is wt-rHCII in
the presence of glycosaminoglycans in a more complex assay
setting.
DISCUSSION
We have “serpendipitously” constructed an HCII mutant
that is a significantly better inhibitor of thrombin than the
wild-type molecule. This mutant, rHCII-CHis6, is a carboxyl-
terminal hexahistidine-tagged heparin cofactor II. In the ab-
sence of glycosaminoglycan we see a small increase in rates of
thrombin inhibition. In the presence of heparin, rHCII-CHis6
has antithrombotic activity that reaches rates comparable to
those of the physiologic thrombin inhibitor ATIII. Addition of
the hexahistidine tag to HCII also increases the affinity of this
molecule for heparin. In contrast, the enhanced activity of
rHCII-CHis6 is not seen with other sulfated polysaccharides
like dermatan sulfate, desmin, or fucoidan. Our results dem-
onstrate that the activity is solely a result of the addition of the
carboxyl-terminal histidine tag and that rHCII-CHis6 func-
tions to inhibit thrombin through the same mechanism as
wt-rHCII, which is highly dependent on ABE-1 of thrombin.
Augmentation of heparin cofactor activity in rHCII-CHis6 is
reversible by CPA proteolysis. We also presented another mu-
FIG. 4. Inhibition of thrombin by wt-HCII, rHCII-CHis6, rHCII-
CAla6, and rHCII-CLys6 in the presence of glycosaminoglycans.
Thrombin inhibition assays in the presence of glycosaminoglycans were
performed with a-thrombin and increasing amounts of heparin (top
panel) or dermatan sulfate (bottom panel) comparing wt-rHCII (M),
rHCII-CHis6 (L), rHCII-CAla6 (E), and rHCII-CLys6 (‚). The curves
shown are the averages of two recombinant protein preparations as-
sayed three times each.
FIG. 5. Inhibition of thrombin and Factor Xa by rATIII mu-
tants in the presence of heparin. Thrombin or Factor Xa assays in
the presence of heparin were performed as detailed under “Experimen-
tal Procedures” with a-thrombin (top panel) or Factor Xa (bottom panel)
and increasing amounts of heparin comparing plasma purified ATIII
(M), wt-rATIII (f), and rATIII-CHis6 (●). The curves are the averages of
two or three protein preparations assayed two to three times each.
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tant, rHCII-CHis5Pro, which retains the enhanced activity but
is resistant to CPA. We also showed that the addition of a
carboxyl-terminal hexahistidine tag to ATIII actually inter-
feres with the ability of ATIII to inhibit two of its target serine
proteases, thrombin and Factor Xa, and has no influence on the
heparin binding of the molecule. This contrast in activity be-
tween HCII and ATIII with a carboxyl-terminal hexahistidine
tag is especially notable since their reactive site loops are very
similar in sequence and in length (1, 27). Therefore, the in-
crease in antithrombin activity is not a general phenomenon
for glycosaminoglycan-binding serpins.
Previous work has indicated that when the hexahistidine tag
is left attached, it rarely affects the properties of the native
protein (28–30). However, we have not found any examples of
heparin-binding proteins being hexahistidine-tagged anywhere
in the literature. This was the point at which we made our
serendipitous finding.
As described in the Introduction, HCII is believed to inhibit
thrombin through an unusual mechanism in the presence of
glycosaminoglycan (2, 14, 20–25). Since the enhanced activity
of the hexahistidine tag was only seen with the glycosamin-
oglycan-binding serpin HCII but not ATIII, the data presented
support the concept that the D-helix region-acidic domain in-
teraction is altered. The increase in antithrombin activity of
rHCII-CHis6 suggests that the acidic domain may be in an
altered conformation to more easily encounter thrombin
ABE-1. Data presented describing inhibition in the presence of
hirugen, a peptide of the carboxyl-terminal region of hirudin,
indicate that ABE-1 of thrombin is still very important in the
mechanism of thrombin inhibition by rHCII-CHis6. This is
further supported by inhibition of gT-thrombin, a proteolyzed
form of thrombin defective at ABE-1. However, the slight re-
sidual increased activity of rHCII-CHis6 toward gT-thrombin
might imply that other residues of ABE-1 not perturbed by
proteolysis (or blocked by hirugen in a-thrombin) might be
involved in this inhibition reaction. The increased binding of
rHCII-CHis6 to heparin-Sepharose compared with wt-rHCII
also lends support to the notion that part of the D-helix region
is more accessible to heparin interaction. The reduced heparin
concentration needed for peak activity for rHCII-CHis6 is re-
lated to heparin-Sepharose affinity and is consistent with that
seen previously for heparin binding characteristics and activity
for heparin-binding serpins (3, 42). The change in heparin but
not dermatan sulfate binding of rHCII-CHis6 further implies
that the glycosaminoglycan-binding site of HCII has both dis-
tinct and overlapping structural elements for heparin and der-
matan sulfate interactions and agrees with previous variants/
mutants of HCII altered in the D-helix region (23, 24). The
comparable inhibition rates of wt-rHCII and rHCII-CHis6 with
chymotrypsin (which does not use either the acidic domain of
HCII or glycosaminoglycans for inhibition) indicate that the
reactive site loop has not been altered to an “activated” confor-
mation, further implicating an alteration between the D-helix/
acidic domain regions in the increased activity of rHCII-CHis6.
It is also possible that these results could be due to the
addition/exposure of a secondary heparin-binding site or some
other effect of the hexahistidine on the conformation of HCII.
Morgan and co-workers (43–45) have published extensively on
the function of histidine-proline-rich glycoprotein as a heparin-
binding molecule. This protein is notable for its tandem histi-
dine-rich repeats that bind heparin either in the presence of
divalent cations or at sub-physiologic pH values. All of our
experiments were carried out at physiologic pH and in the
absence of added divalent cations. Trace metal contamination
is an unlikely source of our results since the control CPA-
digested proteins are treated with EDTA and still maintain
enhanced activity and heparin binding. The lack of effect on the
heparin binding ability of ATIII also argues against the addi-
tion of a new heparin-binding site in either ATIII or HCII due
to the hexahistidine tag itself. To address further the mecha-
nism of hexahistidine and HCII, we then focused our work both
on the composition of the tag and the influence of the amino-
terminal acidic domain region of HCII.
We explored the contribution of the amino-terminal acidic
domain of HCII to the enhanced activity of rHCII-CHis6 by
sequentially deleting the first 52, 68, or 75 amino acids from
either wt-rHCII or rHCII-CHis6. In 1991, van Deerlin and
Tollefsen (22) described similar amino-terminal deletion mu-
tants of HCII. Our data for deletions of wt-rHCII are in agree-
ment with their results. No function has been assigned to the
first 52 amino acids. However, within residues 53 and 75 there
are 13 acidic amino acids (Asp, Glu, and sulfated-Tyr). These
residues are grouped in two distinct clusters called “acidic
region 1” and “acidic region 2” (AR-1 and AR-2). When glyco-
saminoglycans bind the D-helix of HCII it is believed that AR-2
is displaced, which allows AR-1 to be more accessible to bind
ABE-1 of thrombin (22). The removal of amino acids 1–52
should be relatively benign based on this model of HCII. How-
ever, the removal of amino acids 1–68 or 1–75 should influence
the interaction of HCII with thrombin, especially in the pres-
ence of glycosaminoglycans.
In the absence of glycosaminoglycan, the deletion mutants of
wt-rHCII had no major loss of protease inhibition activity.
Based on the results, the amino-terminal region of wt-HCII is
not significantly involved in the inhibition of chymotrypsin or
thrombin. In contrast, all three deletions in rHCII-CHis6 lead
to significant losses of both thrombin and chymotrypsin inhi-
bition. The losses found in inhibition must be due to the pres-
ence of the hexahistidine tag in rHCII-CHis6. Most likely the
tag in the deletion mutants causes a change in the reactive site
loop region of HCII since inhibition is dependent on this struc-
ture. These results suggest that either the amino-terminal
TABLE IV
Inhibition of thrombin activity in plasma
Inhibition of thrombin activity (1 nM) in the presence of wt-rHCII and rHCII-CHis6 (10 nM) and glycosaminoglycan in normal human reference
plasma (REF), antithrombin III-deficient human plasma (DEF) or a 50:50 mixture of these plasmas (REF/DEF). Inhibition rates are given as the
average inhibition rate 6 S.D. These assays were performed as described under “Experimental Procedures.”
Plasma addition
Inhibition ratea k2 3 10
8
Heparin (1 mg/ml) Dermatan sulfate (50 mg/ml)
wt-rHCII rHCII-CHis6 wt-rHCII rHCII-CHis6
M
21min21
Normal reference (REF) 2.2 6 0.17 3.3 6 0.37b 5.7 6 0.45 7.2 6 0.55c
ATIII-deficient (DEF) 0.26 6 0.050 1.2 6 0.10b 6.5 6 0.50 7.5 6 0.59c
50:50 mixture (REF/DEF) 1.9 6 0.050 2.8 6 0.18b 5.8 6 0.24 7.0 6 0.48c
a Rate constants are the mean values of 3–6 determinations with 3 different preparations of recombinant proteins.
b p # 0.001 compared with wt-rHCII.
c p # 0.01 compared with wt-rHCII.
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acidic domain shields the reactive site loop from the hexahis-
tidine tag or it interacts with the hexahistidine tag to then keep
the tag from perturbing the reactive site loop.
In the presence of glycosaminoglycan, the thrombin inhibi-
tion rates are only slightly affected by deletion of the first 52
amino acids of wt-rHCII. In the presence of heparin or derma-
tan sulfate, the loss of residues 1–68 or 1–75 leads to decreased
antithrombotic activity, in agreement with the accepted model
of HCII. However, the rates of thrombin inhibition by the
rHCII-CHis6 deletions are somewhat different. The enhanced
heparin cofactor activity of rHCII-CHis6 is lost with the dele-
tion of the first 52 amino acids. As expected, the 1–68 and 1–75
deletions caused a large loss of activity with both heparin and
dermatan sulfate. The progressive loss of activity indicates that
the protective effect the amino-terminal region of HCII imparts
on the hexahistidine tag is partially mediated between residues
52 and 75. We believe these data provide evidence for the
importance and specificity of an HCII carboxyl terminus (hexa-
histidine tag) and amino-terminal acidic domain interaction.
Since there is no crystal structure of HCII, the data imply that
the amino terminus may be in close proximity to the carboxyl
terminus.
We compared rHCII-CHis6, rHCII-CAla6, and rHCII-CLys6
to provide information about the character of the carboxyl-
terminal hexapeptide tag. We hypothesized that if the en-
hanced activity of rHCII-CHis6 was a result either of the extra
length or of partial positive charge on the tag, then a hexa-
alanine or a hexalysine tag could be used to probe this phe-
nomenon further. We found that only the hexahistidine or
hexa-alanine tag increased the rate of thrombin inhibition in
the absence of glycosaminoglycan. The inhibition of another
serine protease, chymotrypsin, is not affected by the addition of
each tag. These experiments provide evidence that the rate
increases seen with the hexahistidine tag are not fully a result
of charge on the tag, but changes in thrombin inhibition do
further suggest that the acidic domain-D-helix interaction is
perturbed.
In the presence of heparin we see a large increase in the rate
of thrombin inhibition by rHCII-CHis6 and a shift to a lower
heparin requirement. In contrast, with rHCII-CAla6 and rH-
CII-CLys6, we see either a loss or no change in activity. In the
presence of dermatan sulfate we do not observe increased rates
of thrombin inhibition when comparing rHCII-CHis6 to wt-
rHCII. The hexa-alanine and hexalysine tags actually are det-
rimental to the inhibition of thrombin in the presence of der-
matan sulfate. The increase in both dermatan sulfate and
heparin binding by rHCII-CLys6 implies that this protein may
have less specific glycosaminoglycan binding abilities than the
altered binding properties of rHCII-CHis6. These data indicate
that neither the positive charge nor the addition of six amino
acids to the carboxyl terminus of HCII is solely responsible for
increased heparin binding. However, these results do suggest
that the increase in rates of rHCII inhibition with heparin
seems to be specific to the hexahistidine tag.
Current antithrombotic therapies include heparin, low mo-
lecular weight heparin, and other heparinoids, oral anticoagu-
lants such as warfarin, synthetic molecules such as Argatro-
ban, and naturally occurring peptides isolated from
hematophagous parasites, most notably hirudin (46–48). En-
gineered protease inhibitors and proteases are being investi-
gated as anticoagulant therapies (49–55). Chimeric anticoagu-
lants or serpins with specifically engineered reactive site loops
have been described (51–55). Recombinant HCII-CHis6 may
offer some unique advantages over currently available treat-
ments. In the presence of heparin, the activity of rHCII-CHis6
is comparable to that of the physiologic inhibitor ATIII. The
histidine-tagged HCII functions optimally at a significantly
lower heparin concentration than does wild-type HCII. In a
plasma-based assay, we also see increased antithrombotic ac-
tivity of rHCII-CHis6 with both heparin and dermatan sulfate.
Unlike ATIII, HCII is a very specific anticoagulant with its
activity being targeted to thrombin in the coagulation cascade.
Carboxypeptidase A activity has been reported in plasma (56),
and rHCII-CHis6 is susceptible to CPA digestion. This could
allow for the eventual degradation of rHCII-CHis6 to a less
active protein, thus acting as a “temporary” thrombin inhibitor.
In addition, we found rHCII-CHis5Pro has increased anti-
thrombin rates at low heparin concentrations but is resistant to
CPA proteolysis. This HCII mutant could be a “longer acting”
version of the same anticoagulant therapy. Recombinant HCII-
CHis6 derivatives could offer a novel alternative to existing
anticoagulant therapy.
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